TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE) announced that the Company's request for an extension of its previously announced stay of proceedings under the Companies' Creditors Arrangement Act (the "CCAA") was heard before the Ontario Superior Court of Justice (Commercial List) (the "Court") on April 18, 2024 and the decision was reserved.
On April 22, 2024, the Court issued its decision terminating CCAA proceedings and appointing FTI Consulting Canada Inc. as receiver of Antibe.
The Company also announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe's Board of Directors. In addition, the Company today received notification from the TSX that it will be delisting Antibe's common shares from the TSX effective as of May 24, 2024.
Contacts
Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
christina@antibethera.com
